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OBJECTIVES The aim of the present study was to test the hypothesis that retrovirus-mediated in vivo tissue
factor pathway inhibitor (TFPI) gene transfer to the arterial wall would efficiently inhibit
thrombosis without causing significant changes in systemic hemostatic variables.
BACKGROUND Acute coronary syndromes (unstable angina and acute myocardial infarction) are usually
caused by atherosclerotic plaque rupture, with consequent activation of the coagulation
cascade and circulating platelets. Tissue factor (TF) exposure represents an early event in this
pathophysiologic sequence, leading to activation of the extrinsic coagulation pathway and
thrombin formation. Tissue factor pathway inhibitor is a naturally occurring inhibitor of the
extrinsic pathway.
METHODS In the present study, the gene coding for rabbit TFPI was inserted in a retroviral vector under
control of a tetracycline-inducible promoter. Replication-defective, infectious, recombinant
retroviruses were used to transfect rabbit carotid arteries with either TFPI or a reporter
gene—green fluorescent protein (GFP).
RESULTS Retroviral-mediated arterial gene transfer of TFPI resulted in potent inhibition of intravas-
cular thrombus formation in stenotic and injured rabbit carotid arteries, whereas transfection
of the contralateral carotid artery with GFP had no effect on thrombosis. No significant
changes in systemic hemostatic variables (prothrombin time and partial thromboplastin time)
were observed when thrombosis was inhibited.
CONCLUSIONS These data suggest that retroviral-mediated transfection of the arterial wall with TFPI might
represent an attractive approach for the treatment of thrombotic disorders. (J Am Coll
Cardiol 2001;38:569–76) © 2001 by the American College of Cardiology
Plaque rupture or ulceration represents a threatening com-
plication of coronary atherosclerosis, even when the plaque
itself does not significantly obstruct the arterial lumen (1).
Plaque complication is usually associated with formation of
an intracoronary thrombus, which may lead to the abrupt
conversion from chronic to acute coronary syndromes, such
as unstable angina, acute myocardial infarction and sudden
coronary death (2).
Currently, treatment of acute coronary syndromes is
based on the systemic administration of compounds that
inhibit platelet aggregation and thrombin activity or pro-
mote fibrinolysis (1). However, because these compounds
require systemic administration and do not act selectively
only at the site of thrombus formation, a major drawback of
this approach is related to the possible occurrence of serious
side effects—namely, bleeding complications at sites distant
from their intended site of action.
One of the key events responsible for thrombus formation
after plaque rupture is the activation of the extrinsic coag-
ulation pathway, triggered by exposure of tissue factor (TF)
to flowing blood. Tissue factor, a transmembrane glycopro-
tein, complexes with circulating factors VII and VIIa,
permitting enzymatic activation of factors X and IX, which
are the substrates for factor VIIa (3), and ultimately leading
to thrombin formation. Several experimental (4–6) and clinical
(7–9) studies have clearly established that TF-dependent acti-
vation of the coagulation cascade represents an important
determinant of intravascular thrombus generation.
Tissue factor procoagulant activity is modulated in vivo
by a natural inhibitor that is produced by endothelial cells,
known as tissue factor pathway inhibitor (TFPI), a Kunitz-
type serine protease inhibitor. The extrinsic coagulation
pathway is inhibited by TFPI in two different steps: first,
TFPI binds to the active site of factor Xa, thus blocking its
enzymatic activity. Subsequently, the complex TFPI–factor
Xa is capable of binding to the previously formed complex
TF–factor VIIa, thus preventing further formation of factor
Xa (10,11). Recombinant human TFPI (rTFPI) has been
successfully produced and has been shown to be effective in
preventing thrombus formation in a variety of experimental
models (12–14). However, systemic administration of rTFPI
as an antithrombotic intervention requires the use of large
doses, which may entail significant hemorrhagic risks (14).
The rapid progress of in vivo gene transfer technologies
has created powerful new tools to transfer foreign genes into
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the cells of a variety of organs, including the vascular wall. In
1989, Nabel et al. (15) and Wilson et al. (16) demonstrated
the feasibility of transfecting blood vessels with foreign
deoxyribonucleic acid (DNA) in vivo, so that local gene
expression can be readily achieved in defined segments of a
given artery. Since then, different vectors have been devel-
oped to efficiently transfect target cells, including retroviral,
adenoviral and direct DNA transfer (for a recent review on
gene therapy, see reference 17). Thus, the aim of the present
study was to test the hypothesis that retrovirus-mediated in
vivo TFPI gene transfer to the arterial wall would efficiently
inhibit thrombosis without causing significant changes in
systemic hemostatic variables.
METHODS
Preparation of recombinant retroviruses. Rabbit coronary
endothelial cells were harvested and cultured as previously
described (18). Total ribonucleic acid (RNA) was extracted
from rabbit coronary endothelial cells according to the meth-
ods of Chomczynski and Sacchi (19). The complete comple-
mentary DNA (cDNA) of rabbit TFPI was obtained by
reverse transcription polymerase chain reaction (PCR) using
esanucleotide random primers and by PCR using the following
specific primers: forward 59AGGGATCCAGTTTTACT-
CAGTT-GATCT-39; reverse 39-CGAAGCTTGCTTTT-
CTATTACAACAAAC-59, corresponding to the full-length
rabbit TFPI molecule, including the pre-pro signal peptide.
The underlined sequences correspond to BamHI and HindIII
restriction sites, respectively. The PCR product was subcloned
into pT7 blue vector (Novagen, San Diego, California), di-
gested with HindIII and BamHI and cloned into the prokary-
otic expression vector, pRSET-C (Invitrogen, San Diego,
California). This vector contains a sequence coding for
6-histidine residues, so that a fusion protein is obtained with
the 6-histidine tag at the C-terminal. The histidine tag was
later used to differentiate the wild-type TFPI from the recom-
binant protein by immunohistochemistry and by a two-
antibody sandwich assay (see subsequent text).
The TFPI sequence plus the 6-histidine sequence, con-
tained in the pRSET-C vector, was again amplified by PCR
using the following primers: forward 59GGGATATCA-
CTCAGCATAAT-39; reverse 39CGCGGCCGCCTTT-
TCTATTACAA-CAAAC-59. The underlined sequence
corresponds to a NotI restriction site. The PCR product was
subcloned into pCR 2.1 TOPO vector (Invitrogen) and
digested with NotI, thus giving rise to a DNA fragment
with two NotI ends containing the TFPI and the histidine
tag sequence. This fragment was finally cloned into a
retroviral vector, pRETRO-ON (Clontech, Palo Alto, Cal-
ifornia), which is a Moloney murine leukemia virus-derived
retroviral vector expressing the reverse tetracycline-
controlled transactivator (rtTA) from the SV40 promoter.
RtTA is a fusion of amino acids 1-207 of the tetracycline
repressor and the negatively charged C-terminal activation
domain of the VP16 protein of herpes simplex virus. The
tetracycline-responsive element controls expression of the
gene of interest cloned into the multiple cloning site. In the
presence of the tetracycline derivative (i.e., doxycycline),
rtTA binds the tetracycline-responsive element and acti-
vates transcription of the gene of interest, although when
doxycycline is removed from the medium, transcription is
turned off in a highly dose-dependent manner (20). The
59-long terminal repeat controls expression of the transcript
that contains psi (C), the extended retroviral packaging
signal. pRETRO-ON can be transfected into a high-titer
packaging cell line and can thereby mediate production of
infectious, replication-incompetent retroviral particles (21).
The pRETRO-ON retroviral genome lacks the viral genes
gag, pol and env, which are supplied by the packaging cell
line. The transcript produced by the pRETRO-ON con-
struct is recognized by the viral structural proteins in a
packaging cell line and is packaged into infectious retroviral
particles. Because the RNA transcript packaged in these
particles does not contain the viral genes, it cannot replicate
in the target cells that it infects (21).
The DNA sequence coding for the green fluorescent
protein (GFP), as a reporter gene, was obtained by digesting
pEGFP-N1 (Clontech) with NotI and BamHI and cloned
into pRETRO-ON. Both recombinant retroviruses (retro-
TFPI and retro-GFP) were produced by in vitro transfec-
tion of Phoenix packaging cells (purchased from American
Type Culture Collection), yielding high-titer, recombinant,
infectious, replication-defective retroviruses. Virus titer was
assessed using rabbit smooth muscle cells (SMCs) as target
cells and expressed as colony forming units (cfu)/ml. Ret-
roviral stocks with a titer of 1 3 107 cfu/ml were collected
and kept at 280°C until use.
In vitro infection of rabbit SMCs and induction of
recombinant proteins. Rabbit SMCs were harvested from
the thoracic aorta and cultivated in 100-mm tissue culture
dishes in Dulbecco’s modified Eagles medium (DMEM)
supplemented with 10% heat-inactivated calf serum,
100 U/ml penicillin and 100 U/ml streptomycin, as previ-
ously described (22). Twenty-four hours before the experi-
ment, the SMCs were removed from culture dishes by brief
exposure to 0.3% trypsin/0.02% egtazic acid and seeded
onto 24-well culture plates at a density of 3 to 5 3 104/cm2.
On the day of the experiment, the medium was removed
and the retrovirus-containing medium was diluted 1:2 with
Abbreviations and Acronyms
CFV 5 cyclic flow variation
DMEM 5 Dulbecco’s modified Eagles medium
GFP 5 green fluorescent protein
PBS 5 phosphate-buffered saline
PCR 5 polymerase chain reaction
PT 5 prothrombin time
PTT 5 partial thromboplastin time
SMC 5 smooth muscle cell
rtTA 5 reverse tetracycline-controlled transactivator
(TF)PI 5 (tissue factor) pathway inhibitor
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fresh DMEM containing polybrene (4 mg/ml) and added to
the SMC culture. Six hours later, the retrovirus was re-
moved and fresh DMEM was added. Twenty-four hours
later, recombinant protein expression (either TFPI or GFP)
was induced in infected SMCs by addition of doxycycline at
a final concentration of 2 mg/ml. Conditioned media from
these cultures were removed and used later for measurement
of TFPI activity by a two-antibody sandwich assay (see
subsequent text), whereas SMCs from the same cultures
were fixed in 2% buffered paraformaldehyde at the following
time points: 30 min and 1, 2, 4, 8, 12 and 24 h after addition
of doxycycline. In SMCs infected with retro-TFPI, immu-
nofluorescence was performed using a mouse monoclonal
antibody against the 6-histidine tag, as the primary anti-
body, and an anti-mouse immunoglobulin (Ig)G goat poly-
clonal antibody was conjugated with fluorescein. The SMCs
infected with retro-GFP were directly observed under an
ultraviolet fluorescence microscope.
Measurements of rTFPI levels in the medium of
retroviral-transfected SMCs in vitro. Levels of rTFPI in
the medium obtained from SMCs transfected in vitro with
retro-TFPI were measured using a two-antibody sandwich
assay. Briefly, a 20-mg/ml solution of a purified goat IgG
anti-rabbit TFPI (a generous gift from Dr. Mirella Ezban,
Novo Nordisk A/S, Gentofte, Denmark) was incubated in
enzyme-linked immunosorbent assay microtiter plates for
2 h at room temperature. After washing the plates four
times with phosphate-buffered saline (PBS), the plates were
blocked with a 3% bovine serum albumin solution in PBS
overnight at room temperature. After washing with PBS,
50 ml of the culture medium obtained from the SMCs
transfected in vitro with retro-TFPI were added to the wells
and incubated for 2 h at room temperature. The wells were
washed again four times with PBS, and a 1:2,000 dilution of
a peroxidase-conjugated mouse monoclonal antibody di-
rected against the 6-histidine tag was added to the wells for
2 h. After extensive washing with PBS, the reaction was
developed by adding tetramethylbenzidine (10 mg/ml in 0.1
mol/liter sodium acetate, pH 6.0) and H2O2 0.01%. After
30 min, the reaction was stopped by adding 50 ml of 1
mol/liter H2SO4, and the plates were read in a microtiter
plate reader at 450 nm.
Local in vivo delivery of recombinant retroviruses. New
Zealand White rabbits were anesthetized with ketamine
(35 mg/kg) and xylazine (10 mg/kg) intramuscularly. In a
first group of six rabbits, both carotid arteries were exposed
through a median incision of the neck, and a segment of
both arteries was injured by gently squeezing it between a
pair of rubber-covered forceps. Damage of the carotid
arteries was performed to induce proliferation of the cells of
the arterial wall, because it is known that retroviruses infect
proliferating cells more efficiently (17). Heparin was admin-
istered (100 IU/kg, intravenous bolus) to avoid thrombosis
of the damaged vessels, the surgical wounds were sutured
and the animals were allowed to recover. The following day,
the animals were anesthetized again, both carotid arteries
were exposed and the damaged segment was isolated from
the circulation through atraumatic microvascular clamps. A
small polyethylene catheter (25-gauge outer diameter) was
placed into the carotid artery, the content of the lumen was
aspirated and the lumen was washed with 200 ml of PBS.
Then, 200 ml of 1 3 107 cfu/ml retro-TFPI or retro-GFP
was injected into the clamped vascular segments and kept in
place for 30 min. Randomly, one carotid artery was infected
with retro-TFPI and the other one with retro-GFP. After
30 min, the retrovirus-containing medium was aspirated
back into the catheter, and the vascular clamps were
removed. Heparin was administered again (100 IU/kg), and
the animals were allowed to recover.
In a second group of six animals, the carotid arteries were
infected with retro-TFPI or retro-GFP, as previously de-
scribed, except that the arterial damage was not performed.
These experiments were performed to establish whether the
recombinant retroviruses could also infect intact arterial walls.
In vivo model of intravascular thrombus formation. The
antithrombotic effects of transfecting the arterial wall with
retro-TFPI were evaluated using a rabbit model of recurrent
carotid artery thrombosis, as described in detail elsewhere
(23,24). Briefly, 48 h after transfection, the rabbits were
anesthetized again with a mixture of ketamine (35 mg/kg)
and xylazine (5 mg/kg) administered intramuscularly. An-
esthesia was maintained during the course of the experiment
by an intravenous infusion of ketamine sufficient to abolish
the corneal reflex. Through a median incision of the neck, the
left and right common carotid arteries were exposed again.
Polyethylene catheters were inserted into a jugular vein and a
femoral artery for both drug administration and blood pressure
monitoring. Segments of the exposed vessels distal to the sites
of transfection were injured again by gently squeezing the
arteries between a pair of rubber-covered forceps. An external
plastic constrictor was placed around each damaged site.
Carotid blood flow velocities in both arteries were simulta-
neously and continuously measured by Doppler flow probes
positioned proximal to the constrictor. After instrumentation,
the animals developed cyclic fluctuations of carotid blood flow
(cyclic flow variations [CFVs]), characterized by gradual de-
creases of flow to almost zero values, followed by spontaneous
or induced restorations of flow. Previous studies have shown
that CFVs are caused by recurrent cycles of thrombus forma-
tion and subsequent dislodgment (23,24).
After observing CFVs in both carotid arteries for 30 min,
doxycycline was administered as an intravenous bolus of
3 mg/kg, followed by a continuous infusion of 300 mg/kg
body weight per min to induce expression of the recombi-
nant proteins (i.e., TFPI and GFP). Carotid blood flow
velocities in both arteries were continuously measured until
CFVs were abolished, at which time the animals were
observed for an additional hour.
Immunohistochemical evaluation of recombinant pro-
tein expression. At the end of the experiment, both carotid
arteries were isolated, rinsed with saline, fixed in 4%
buffered neutral formalin and embedded in paraffin. Serial
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sections (5 mm) were mounted on coated slides and, once
deparaffinized, immunostained using a peroxidase-
conjugated monoclonal antibody against the 6-histidine tag
(Sigma Chemicals, St. Louis, Missouri) for 1 h at 37°C.
Peroxidase activity was visualized using 3-amino-9-ethyl-
carbazole (AEC, Sigma) as substrate. After immunostain-
ing, the sections were lightly counterstained with hematox-
ylin. As negative control samples, arterial sections were
incubated with an unrelated antibody (Anti-Xpress, Invitro-
gen)—a mouse monoclonal antibody directed against the
leader peptide, Asp-Leu-Tyr-Asp-Asp-Asp-Asp-Lys, in-
stead of the one against the 6-histidine tag—and were
further processed according to the same procedure described
earlier. Arterial sections were obtained from animals sub-
jected or not to previous arterial injury. As an additional
internal control, the sections were obtained from animals
under uninduced conditions (i.e., no doxycycline infusion)
or from animals receiving doxycycline infusion.
RESULTS
In vitro infection of rabbit SMCs and induction of
recombinant proteins. Immunofluorescence performed on
rabbit SMCs transfected in vitro with either a recombinant
retrovirus containing the gene of rabbit TFPI (retro-TFPI)
or a control retrovirus containing a reporter gene (i.e.,
retro-GFP) is shown in Figures 1 and 2. At baseline, that is,
in SMCs transfected but under uninduced conditions, no
detectable expression of recombinant TFPI or GFP could
be detected. In contrast, a time-dependent induction of
recombinant TFPI was observed after addition of doxycy-
cline to the medium, peaking at 12 to 24 h. The use of a
specific antibody directed against the 6-histidine tag,
present only in the recombinant TFPI, allowed us to detect
only the recombinant protein and not the wild-type TFPI,
which is known to be produced also by SMCs (25). In
addition, no fluorescence was detected in SMCs transfected
with retro-GFP or with a retrovirus not containing any
recombinant gene 24 h after induction (Fig. 1), thus
indicating a lack of nonspecific cross reactivity of the
antibody with a cellular or retroviral component. The SMCs
transfected with GFP showed a similar pattern of GFP
expression (Fig. 2).
Measurement of TFPI levels in the culture medium of
SMCs transfected with retro-TFPI, by a two-antibody
sandwich assay, also revealed a time-dependent increase in
TFPI levels after induction with doxycycline, which also
Figure 1. Time course of recombinant tissue factor pathway inhibitor (TFPI) expression in rabbit smooth muscle cells (SMCs) transfected in vitro with
a recombinant retrovirus containing the gene of rabbit TFPI. The SMCs were probed with a monoclonal antibody directed against a 6-histidine tag present
only on the recombinant protein, thus allowing differentiation of rTFPI from the wild-type protein. After induction of rTFPI with the addition of
doxycycline in the culture medium, a progressive increase in rTFPI expression was observed, peaking at 12 to 24 h, although no significant expression was
observed at baseline (i.e., uninduced conditions) or in SMCs transfected with a retrovirus containing the gene of GFP or a control retrovirus (pRETRO).
See text for details.
Figure 2. Time course of green fluorescent protein (GFP) expression in rabbit smooth muscle cells (SMCs) transfected in vitro with a recombinant
retrovirus containing the gene of GFP. Because GFP is spontaneously fluorescent when observed under ultraviolet light, the SMCs were directly observed
under an ultraviolet microscope. After induction of GFP with the addition of doxycycline in the culture medium, a progressive increase in GFP expression
was observed, peaking at 12 to 24 h, although no significant expression was observed at baseline (i.e., uninduced conditions). See text for details.
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peaked at 12 to 24 h (Fig. 3). Also, in this case, by using the
antibody against the 6-histidine tag, we were able to measure
only the concentration of rTFPI in the medium. In addition,
rTFPI levels in the medium obtained from SMCs transfected
with retro-GFP were unmeasurable (data not shown).
In vivo antithrombotic effects of retroviral TFPI trans-
fection. In group I rabbits (i.e., animals subjected to vessel
injury before retroviral transfection), CFVs, which are an
expression of recurrent thrombosis, were induced in both
vessels in all animals after the second endothelial damage,
followed by placement of the constrictor around the carotid
artery. The CFV frequency averaged 12.3 6 4.1 and 11.4 6
3.4 cycles/hour in the carotid arteries transfected with
retro-TFPI and retro-GFP, respectively (p 5 NS). After
induction of the recombinant proteins by doxycycline ad-
ministration (3 mg/kg bolus plus 300 mg/kg per min), CFVs
were completely inhibited only in the vessels previously
transfected with retro-TFPI (n 5 6), whereas they re-
mained unchanged in the vessels transfected with retro-
GFP (n 5 6, p , 0.01) (Fig. 4 and 5). The time necessary
to achieve complete inhibition of CFVs after starting
doxycycline infusion averaged 2.5 6 0.6 h. This finding
demonstrates that the antithrombotic effects of retro-TFPI
are related to the secretion of TFPI, because in the same
animal, the contralateral vessel transfected with retro-GFP did
not show any significant change in CFVs. Similar results were
observed in group II animals (n 5 6) that were transfected
without previously damaging the artery (data not shown).
The antithrombotic effects of retro-TFPI were obtained
without significant changes in systemic prothrombin time
(PT) and partial thromboplastin time (PTT), as indicated in
Figure 6.
Immunohistochemical evaluation of recombinant pro-
tein expression. Immunohistochemical studies aimed at
identifying the presence of rTFPI in the transfected arteries
revealed no rTFPI expression in vessels obtained from
animals under uninduced conditions (i.e., not receiving
doxycycline) (Fig. 7A), whereas an intense and diffuse
positivity was evident after administration of doxycycline
(Fig. 7B). No significant differences were observed in rTFPI
expression levels in arterial sections obtained from animals
subjected or not to previous injury (Fig. 7C), indicating that
in this model, previous arterial injury was not necessary to
obtain a significant level of transfection. Arterial sections
probed with an unrelated antibody did not show any
significant positivity (Fig. 7D). Similarly, vessels transfected
with retro-GFP did not show any positivity for the presence
of rTFPI, although they were spontaneously fluorescent due
to the presence of GFP (Fig. 8).
DISCUSSION
The main finding of the present study is that local arterial
expression of TFPI through retrovirus-mediated gene trans-
fer is associated with complete inhibition of intravascular
thrombus formation at the site of arterial damage, without
inducing significant changes in systemic hemostatic vari-
ables, such as PT and PTT. These observations also confirm
the important role of TF-induced activation of coagulation
in the pathophysiology of intravascular thrombus formation
at sites of arterial injury and underline the antithrombotic
efficacy of gene transfer techniques targeted at modulating
TF procoagulant activity.
Accumulating evidence indicates that the complex TF–
factor VIIa is a key initiator of arterial thrombosis in vivo.
Coronary thrombosis generally occurs at sites of a preexist-
ing atherosclerotic plaque, often precipitated by fissuration
or ulceration of the plaque (1). Because atherosclerotic
plaques are rich with TF-synthesizing cells, such as mono-
cytes, foam cells and mesenchymal-like cells, plaque rupture
may lead to exposure of TF to flowing blood (7), binding of
factor VII/VIIa to TF and activation of TF-dependent
coagulation. Several studies have identified both TF antigen
and activity within human atherosclerotic plaques and have
suggested that they may represent an important determinant
Figure 3. Ex vivo secretion of recombinant tissue factor pathway inhibitor
(TFPI) by rabbit smooth muscle cells (SMCs). The rTFPI levels were
measured by a two-antibody sandwich assay, using a monoclonal antibody
against a 6-histidine tag present only in the recombinant protein, thus
excluding the contribution of the wild-type TFPI. A progressive increase in
rTFPI levels was observed, peaking at 12 to 24 h after doxycycline induction.
Figure 4. Representative carotid Doppler flow recordings obtained from a
rabbit after local treatment of one carotid artery with retro-tissue factor
pathway inhibitor (TFPI) and the other one with retro-green fluorescent
protein (GFP). At baseline (i.e., before induction of the recombinant proteins),
cyclic flow variations (CFVs) developed similarly in both carotid arteries. In
contrast, 2 h after induction with doxycycline (3 mg/kg intravenous bolus plus
300 mg/kg per min), CFVs were completely inhibited only in the carotid artery
previously transfected with retro-TFPI, although they remained unchanged in
the vessel previously transfected with retro-GFP.
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of thrombogenicity after plaque rupture (8,9,26). Further-
more, previous studies from our own group have demon-
strated that inhibition of the TF–factor VIIa axis results in
marked antithrombotic effects (4–6).
An important regulator of TF-mediated coagulation
pathway is TFPI, a multivalent protease inhibitor with three
Kunitz-type domains; TFPI inhibits the TF-dependent
coagulation cascade initially by binding factor Xa through
its Kunitz II domain, and subsequently by binding to the
TF–factor VIIa catalytic complex through its Kunitz I
domain (10). This prevents further production of factor IXa
and Xa, as well as auto-activation of factor VII in the factor
VII–TF complex (11). The formation of a quaternary
complex—TF–factor VIIa–TFPI–factor Xa—dampens on-
going coagulation and may allow modulation of thrombosis
in vivo. Important evidence for TFPI as a natural antico-
agulant in vivo is offered by a recent study from our
laboratory, in which we have demonstrated that during
thrombus formation, plasma TFPI activity measured distal
to the site of thrombus formation was significantly lower
than that of samples obtained at a proximal site, suggesting
a direct involvement of TFPI at the site of thrombosis (27).
Furthermore, in that study, we also observed that systemic
plasma TFPI activity decreased during recurrent thrombo-
sis, indicating a progressive consumption of this protein
during the process of thrombus formation (27). Other
studies have shown that exogenous rTFPI was effective in
inhibiting intravascular thrombosis, but this effect was
achieved at doses far higher than those present physiologi-
cally in plasma (12–14). Not surprisingly, considering the
factor Xa inhibitory effects of TFPI, Oltrona et al. (14)
found that systemic administration of rTFPI led to a
marked prolongation in PT, suggesting that rTFPI at doses
effective in preventing arterial thrombosis is associated with
a substantial risk of bleeding.
The main advantage of increasing local TFPI concentra-
tions by gene transfer to the arterial wall is that therapeutic
TFPI levels can be achieved only where they are needed (i.e.,
at the damaged arterial site where TF is exposed), without
concomitant prolongation of PT and PTT. In search of
effective strategies to treat intravascular thrombosis, many
antithrombotic or fibrinolytic substances have been adminis-
tered systemically. Unfortunately, such an approach, although
proven to be effective in exerting significant inhibitory effects
on thrombosis, also tends to induce systemic bleeding (28).
This is obviously an important factor in the determination of
the clinical therapeutic window and underlines the potential
advantage of local gene transfer into the arterial wall as an
effective means of treating intravascular thrombosis.
Previous studies on arterial gene transfer as antithrombotic
interventions. In addition to recombinant hirudin gene
transfer (29), transfection of the arterial wall with cycloox-
ygenase (30), tissue-type plasminogen activator (31), nitric
oxide synthase (32) and thrombomodulin gene (33) has
been demonstrated to be effective in inhibiting intravascular
thrombosis in a variety of experimental models. Two other
studies recently published while the present work was in
progress warrant further discussion, however. Nishida et al.
(34) and Zoldhelyi et al. (35) have reported the antithrom-
botic efficacy of arterial TFPI gene transfer in a rabbit and
porcine model of balloon-injured carotid arteries.
However, important limitations can be identified in these
latter studies. First, Zoldhelyi et al. (35) have transfected
Figure 5. Frequency of cyclic flow variations (CFVs) (cycles/hour) in carotid arteries transfected with retro-tissue factor pathway inhibitor (TFPI) (A) and
carotid arteries transfected with retro-green fluorescent protein (GFP) (B). After induction of the recombinant proteins with doxycycline, CFVs were
completely inhibited only in retro-TFPI transfected vessels, although they remained unchanged in the contralateral arteries transfected with retro-GFP.
Each dot represents one animal.
Figure 6. The prothrombin times (PTs) and partial thromboplastin times
(PTTs) measured at baseline (i.e., uninduced conditions) and at the time of
inhibition of cyclic flow variations (CFVs) after administration of doxycy-
cline. No significant changes in PTs and PTTs were observed when
induction of recombinant human tissue factor pathway inhibitor (rTFPI)
exerted its antithrombotic effects.
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two groups of pigs with either an adenoviral vector contain-
ing the gene of human TFPI or with a control adenovirus.
Thus, this protocol did not allow the investigators to use
each animal as its own control. Second, and perhaps most
important, transfection of the arterial wall with both adeno-
viruses used in the study of Nishida et al. (34) and Zoldhelyi
et al. (35) resulted in constitutive expression of rTFPI. As a
consequence, rTFPI expression was already started at the
time of induction of CFVs, resulting in the impossibility of
inducing CFVs in the vessels transfected with rTFPI.
However, some differences in inducing arterial damage in
TFPI-transfected vessels, compared with the control arter-
ies, cannot be excluded. Finally, Nishida et al. (34) did not
provide unequivocal evidence that transfection of the vessels
was indeed associated with an increase in rTFPI secretion.
In contrast, in the present study, all of these potentially
important limitations have been overcome. For example, an
advantage of the retroviral vector used in the present study
is that the gene of interest is under control of a tetracycline-
responsive element, so that it can be switched on in the
presence of the tetracycline derivative (i.e., doxycycline).
This peculiarity of the vector allowed us to induce the
expression of rTFPI after intravascular thrombosis was
initiated, thus using each animal as its own control. This
also allowed us to clearly establish that the antithrombotic
effects were indeed caused by local expression of rTFPI.
Two lines of evidence indicate that this was the case: first,
after starting doxycycline infusion, CFVs were inhibited
Figure 7. Immunohistochemical staining for recombinant human tissue factor pathway inhibitor (rTFPI) in arterial sections obtained from carotid arteries
transfected with retro-TFPI under uninduced conditions (i.e., no infusion of doxycycline) (A) and after administration of doxycycline to an animal subjected
to a previous injury (B) or after administration of doxycycline to an animal not subjected to a previous arterial injury (C). After doxycycline infusion, a diffuse
and intense reactivity was present across the arterial wall, although no staining was present under uninduced conditions. No significant differences in rTFPI
expression were observed in the arterial wall between the two groups of animals. Recombinant TFPI was probed with a monoclonal antibody against a
6-histidine tag present only in the recombinant protein, thus allowing detection of rTFPI from the wild-type protein. (D) Histologic section of an artery
obtained during doxycycline infusion and probed with an unrelated mouse monoclonal antibody (Anti-Xpress, Invitrogen). No cross reactivity is present
in this section (see Methods for further details).
Figure 8. Detection of green fluorescent protein (GFP) in the arterial wall after transfection with retro-GFP and induction with doxycycline. (A) Section
stained with hematoxylin-eosin. (B) Adjacent section not stained, observed under the ultraviolet microscope equipped with a filter specific for GFP fluorescence.
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only in the carotid artery transfected with retro-TFPI,
although they continued to be unchanged in the contralat-
eral carotid artery transfected with retro-GFP. Second,
immunohistochemistry studies using a specific antibody
against rTFPI that did not cross react with wild-type TFPI
indicated a marked rTFPI expression in the arterial wall
after doxycycline infusion, whereas no expression could be
detected in arteries transfected with retro-GFP. These
findings strongly point toward a specific effect of rTFPI
expression in inhibiting intravascular thrombus formation.
Finally, an additional interesting feature of retroviral vectors
is represented by the fact that they stably integrate into the
genomic DNA of target cells, giving the theoretical advan-
tage over other vectors, such as adenovirus, that expression
of the transfected genes can be maintained for long periods,
probably indefinitely, thus eliciting the possibility of induc-
ing the transfected gene more than once, as needed. How-
ever, the safety of a retroviral approach as a means of
transferring genes into humans remains to be elucidated.
Conclusions. Our study provides evidence that retrovirus-
mediated site-specific TFPI gene transfer into rabbit carotid
arteries eliminates intravascular thrombosis without sys-
temic side effects. The validity of this approach in treating
human thrombotic disorders needs to be determined.
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